Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsOscar Health Aptiom Prior Auth Policy | OpenPayer
    Ask Trek AI about this page
    CurrentOscar HealthPolicy PG174

    Aptiom (eslicarbazepine acetate) Coverage Criteria

    Customize your policy alerts

    Sign up for Oscar Health Policy PG174 alerts

    Get alerted when Policy PG174 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical necessity review for Aptiom (eslicarbazepine acetate) in members aged 4 years and older with focal-onset seizures. It requires specialist involvement, use or failure of alternative antiepileptic drugs, appropriate dosing, and compliance with the quantity limit.

    Policy Summary
    PayerOscar Health
    PolicyAptiom (eslicarbazepine acetate) Coverage Criteria
    Policy CodePolicy PG174
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJan 4, 202747d
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing specialist involvement, focal-onset seizures, two appropriate alternate antiepileptic drug trials, and dosing within policy limits.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Age 4+Minimum member age
    2 alternativesAlternate antiepileptic drugs required
    1 manufacturerGeneric manufacturers required before brand
    60 tablets / 30 daysQuantity limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Up to lifetime
    Authorization duration
    Focal-onset seizuresCovered indication

    Aptiom Coverage Criteria

    Initial Aptiom medical necessity criteria

    Covered when ALL of the following are met:

    Focal seizures medical necessity

    • Prescriber and age

      • Aptiom is prescribed by or in consultation with a neurologist or epilepsy specialist.
      • The member is 4 years of age or older.age >= 4 years
    • The member has a diagnosis of focal seizures, also called partial-onset seizures or partial seizures.
    • The member is unable to use, or has tried and failed, two alternate antiepileptic drugs applicable to the member's age.2 alternate antiepileptic drugs

      Examples include carbamazepine, divalproex, fosphenytoin, lacosamide, lamotrigine, levetiracetam, methsuximide, oxcarbazepine, phenobarbital, phenytoin, pregabalin, primidone, tiagabine, topiramate, valproate sodium, valproic acid, and zonisamide.

    • If the request is for brand Aptiom, the member is unable to use, or has tried and failed, generic eslicarbazepine acetate from one manufacturer.1 generic manufacturer

      Applies only to brand Aptiom requests.

    • Aptiom is prescribed at a dose and frequency within FDA-approved labeling or supported by compendia or evidence-based published dosing guidelines for the requested indication.FDA-labeled or evidence-supported dose and frequency
    • The requested medication is used within the Plan's quantity limit.60 tablets every 30 days

    Experimental, investigational, or unproven uses

    Not covered as experimental, investigational, or unproven:

    Unproven uses

    • Aptiom is used for an indication other than focal-onset seizures, including bipolar I disorder, fibromyalgia, migraine, neuropathic pain including painful diabetic neuropathy or postherpetic neuralgia, or other epilepsies not included in the policy.

      These uses are considered experimental, investigational, or unproven.

    • Aptiom is used as adjunctive therapy with oxcarbazepine.

      This combination is excluded because of overlapping pharmacology and safety risks.

    Adjunctive therapy with oxcarbazepine is not covered. Aptiom should not be taken with oxcarbazepine because the medications have overlapping pharmacology and pose safety risks.

    Aptiom uses other than the covered indication of focal-onset seizures are considered experimental, investigational, or unproven. Non-covered uses include bipolar I disorder, fibromyalgia, migraine, neuropathic pain—including painful diabetic neuropathy and postherpetic neuralgia—and other epilepsies not included in this policy.

    Initial Authorization

    Initial Aptiom authorization

    Initial therapy is covered when ALL of the following are met:

    • Aptiom is prescribed by or in consultation with a neurologist or epilepsy specialist.
    • The member is 4 years of age or older.age >= 4 years
    • The member has a diagnosis of focal seizures, also called partial-onset seizures or partial seizures.
    • The member is unable to use, or has tried and failed, two alternate antiepileptic drugs applicable to the member's age.2 alternate antiepileptic drugs

      Examples include carbamazepine, divalproex, fosphenytoin, lacosamide, lamotrigine, levetiracetam, methsuximide, oxcarbazepine, phenobarbital, phenytoin, pregabalin, primidone, tiagabine, topiramate, valproate sodium, valproic acid, and zonisamide.

    Continuation Authorization

    Continuation authorization duration

    When the prior authorization criteria are met:

    Authorization duration

    • The requested product may be authorized for up to a lifetime when the prior authorization criteria are met.up to lifetime

      State mandates may apply.

    Required Medication Trials

    StepRequirementExamples of alternate drugs
    1The member is unable to use, or has tried and failed, two alternate antiepileptic drugs applicable to the member’s age. Failure may include inadequate seizure control.Carbamazepine; divalproex; fosphenytoin; lacosamide; lamotrigine; levetiracetam; methsuximide; oxcarbazepine; phenobarbital; phenytoin; pregabalin; primidone; tiagabine; topiramate; valproate sodium; valproic acid; or zonisamide.
    StepRequirementApplies to
    2For a request for brand Aptiom, the member is unable to use, or has tried and failed, generic eslicarbazepine acetate from one manufacturer.Brand Aptiom requests

    Aptiom Quantity Limit

    Quantity Limit
    MedicationAptiom (eslicarbazepine acetate)
    Quantity limit60 tablets
    Limit periodEvery 30 days

    Coverage Parameters

    Aptiom Quantity Limit
    ProductAptiom (eslicarbazepine acetate)
    Maximum quantity60 tablets
    Coverage interval30 days
    Minimum Age
    Minimum age4 years
    EligibilityMember must be 4 years of age or older
    Applies toAptiom coverage for focal or partial-onset seizures

    Authorization and Documentation Requirements

    Prior Authorization

    Aptiom Prior Authorization

    Prior authorization is required for Aptiom (eslicarbazepine acetate). Requests are reviewed against the Plan’s medical-necessity criteria for focal-onset seizures.

    Denial Risk

    Clinical Criteria Not Met

    Aptiom is medically necessary only when prescribed by or in consultation with a neurologist or epilepsy specialist, for a member age 4 or older with focal-onset seizures, and when all other applicable criteria are met.

    • The member must have focal seizures, also called partial-onset or partial seizures.
    • The member must be unable to use, or have tried and failed, two age-appropriate alternate antiepileptic drugs.
    • Brand Aptiom requests require inability to use or a failed trial of generic eslicarbazepine acetate from one manufacturer.
    • The requested dose must be within FDA-approved labeling or supported by compendia or evidence-based published dosing guidelines.

    Clinical Background

    Focal-onset seizures, also called partial or partial-onset seizures, begin in a specific region or focus of the brain. Awareness may be preserved or impaired during the event. Aptiom is an antiseizure medication used alone or as adjunctive therapy to reduce the frequency and severity of focal-onset seizures in patients aged 4 years and older; it stabilizes electrical activity in the brain but does not cure the underlying cause of epilepsy.

    Key Terms

    Antiepileptic Drugs
    TermAntiepileptic drugs
    PurposeMedications used to prevent or reduce the severity and frequency of seizures
    Clinical scopeUsed in various types of epilepsy
    Focal-Onset Seizures
    DefinitionSeizures that begin in a specific region or focus of the brain
    Also calledPartial-onset seizures or partial seizures
    TerminologyFocal seizures is the more recently adopted term replacing partial seizures
    Policy Summary
    PayerOscar Health
    PolicyAptiom (eslicarbazepine acetate) Coverage Criteria
    Policy CodePolicy PG174
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJan 4, 202747d
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing specialist involvement, focal-onset seizures, two appropriate alternate antiepileptic drug trials, and dosing within policy limits.
    SourceLink
    On This Page
    Aptiom Coverage CriteriaInitial AuthorizationContinuation AuthorizationRequired Medication TrialsAptiom Quantity LimitCoverage ParametersAuthorization and Documentation RequirementsClinical BackgroundKey Terms
  1. If the request is for brand Aptiom, the member is unable to use, or has tried and failed, generic eslicarbazepine acetate from one manufacturer.1 generic manufacturer

    Applies only to brand Aptiom requests.

  2. Aptiom is prescribed at a dose and frequency within FDA-approved labeling or supported by compendia or evidence-based published dosing guidelines for the requested indication.FDA-labeled or evidence-supported dose and frequency
  3. The requested medication is used within the Plan's quantity limit.60 tablets every 30 days
  4. The request must comply with the quantity limit of 60 tablets every 30 days.
  5. Documentation Required

    Diagnosis and Medical Necessity Documentation

    Submit current documentation supporting the diagnosis and medical necessity of Aptiom with the prior authorization request.

    • Up-to-date chart notes.
    • Relevant test results and/or imaging reports.
    • The member’s diagnosis and focal-seizure history.
    Documentation Required

    Prior Authorization Clinical Details

    Document the clinical details needed for review, including specialist involvement, member age, diagnosis, requested dose and frequency, and other relevant medical information.

    • Identify the prescribing neurologist or epilepsy specialist, or describe the specialist consultation.
    • Document that the member is 4 years of age or older.
    • Specify the focal-onset seizure diagnosis.
    • Provide the requested Aptiom dose and frequency and the indication for use.
    Step Therapy

    Alternative-Drug Trial Evidence

    Document that the member is unable to use or has tried and failed two age-appropriate alternate antiepileptic drugs. Trial evidence should support inadequate seizure control or another applicable reason the alternative cannot be used.

    • Provide prescription claims records and/or prescription receipts for formulary alternatives.
    • Identify the drug name, trial dates or duration when available, dose, and outcome or reason the drug was unusable.
    • Applicable alternatives may include carbamazepine, divalproex, fosphenytoin, lacosamide, lamotrigine, levetiracetam, methsuximide, oxcarbazepine, phenobarbital, phenytoin, pregabalin, primidone, tiagabine, topiramate, valproate sodium, valproic acid, or zonisamide.
    • For brand-product trials, provide documentation of the brand product trial when applicable.
    Step Therapy

    Brand Exception Requirement

    For a request for brand Aptiom, document that the member is unable to use or has tried and failed generic eslicarbazepine acetate from one manufacturer.

    • Provide prescription claims, receipts, or other trial documentation for the generic product.
    • Explain the clinical reason the generic product was unusable or document the outcome of the failed trial.
    Step Therapy

    Generic Eslicarbazepine Acetate Step

    A required step is failure or inability to use generic eslicarbazepine acetate before brand Aptiom can be considered.

    • The generic prerequisite applies when the request is for brand Aptiom.
    • Brand Aptiom may be denied when the required generic trial is not documented.
    Billing Rule

    Dose and Quantity Limit

    Aptiom must be prescribed at a dose and frequency within FDA-approved labeling, or supported by compendia or evidence-based published dosing guidelines for the requested indication. The request must also remain within the Plan’s quantity limit.

    • Quantity limit: 60 tablets every 30 days.
    • Requests exceeding the dose or quantity limit require supporting clinical evidence and may be denied if the excess is not justified.
    Denial Risk

    Clinical Criteria Not Met: Denial Conditions

    A request may be denied when the clinical criteria are not satisfied, including requirements related to age, seizure type, specialist involvement, alternative-drug trials, brand or generic sequencing, dosing, quantity, or medical necessity.

    • Member is younger than 4 years of age.
    • Diagnosis is not focal-onset, partial-onset, or partial seizures.
    • A neurologist or epilepsy specialist is not prescribing or consulting.
    • Two age-appropriate alternate antiepileptic drugs have not been shown to be unusable or tried and failed.
    • Required documentation does not support the diagnosis, trials, dose, frequency, or requested indication.
    Denial Risk

    Generic Prerequisite Not Met

    Brand Aptiom may be denied when the member has not been shown to be unable to use or to have tried and failed generic eslicarbazepine acetate from one manufacturer.

    • Submit evidence of the generic trial or the reason it cannot be used.
    • The generic prerequisite applies specifically to brand Aptiom requests.
    Denial Risk

    Dose or Quantity Limit Exceeded

    Requests for dosing outside FDA labeling or applicable evidence-based guidance, or quantities above 60 tablets every 30 days, may be denied without adequate supporting evidence.

    • Document the requested dose and frequency.
    • Provide compendia or published evidence supporting a nonstandard dose when applicable.
    • Explain and support any requested quantity above the Plan limit.
    Denial Risk

    Uncovered Indication

    Aptiom for uses other than the covered focal-onset seizure indication is considered experimental, investigational, or unproven and is not covered under this policy.

    • Non-covered uses include bipolar 1 disorder, fibromyalgia, migraine, neuropathic pain including painful diabetic neuropathy and postherpetic neuralgia, and other forms of epilepsy not included in this policy.
    • The policy does not support Aptiom for non-focal-onset seizure uses or other unlisted indications.
    Denial Risk

    Unsafe Combination

    Aptiom should not be used as adjunctive therapy with oxcarbazepine because of overlapping pharmacology and safety risks identified in the package insert.

    • Requests combining Aptiom with oxcarbazepine may be denied or require clinical clarification.
    Focal Onset Aware Seizures
    DefinitionA focal-onset seizure in which the individual remains conscious throughout the event
    AwarenessThe individual remains aware throughout the event
    Seizure typeFocal onset aware seizure
    Focal Onset Impaired Awareness Seizures
    DefinitionA focal-onset seizure that affects the individual's consciousness or awareness during the event
    EffectConsciousness or awareness is impacted during the event
    Seizure typeFocal onset impaired awareness seizure
    Documentation
    DefinitionWritten information supporting diagnoses or prior trials of formulary alternatives
    Clinical recordsUp-to-date chart notes, relevant test results, and/or relevant imaging reports
    Pharmacy recordsPrescription claims records and/or prescription receipts